

Abstracts

Submit your latest research in the cancer immunotherapy field to SITC 2019 for consideration as an oral abstract presentation, rapid oral abstract presentation, and/or poster abstract presentation.

Reasons to Submit an Abstract to SITC 2019

- Submissions are free for members and nonmembers alike
- SITC offers Young Investigator Awards in conjunction with regular abstract submission
- We publish all accepted abstracts as a supplement in the Journal for ImmunoTherapy of Cancer (JITC), the society's global, open access, peer-reviewed journal
- Over 75 oral presentation opportunities are available
- The opportunity to present and discuss your research with luminaries in the immunotherapy field

Important Abstract Dates

Aug. 1, 2019	Regular Abstracts, Young Investigator Award Abstracts, Late-Breaking Abstracts Application Site Closes at 5 p.m. PDT
Aug. 23, 2019	Late-Breaking Abstract Submission Site Opens*
Aug. 30, 2019	Regular Abstract and Young Investigator Award Abstract Notifications Sent
Sept. 12, 2019	Late-Breaking Abstract Submission Site Closes at 5 p.m. PDT*
Sept. 23, 2019	Late-Breaking Abstract Notifications Sent
Nov. 5, 2019	Regular Abstract Supplement Published in JITC
Dec. 5, 2019	Late-Breaking Abstract Supplement Published in JITC

For more information on abstract submission at SITC 2019, please visit sitcancer.org/2019

*A late-breaking abstract application must be submitted by Aug. 1 at 5 p.m. PDT to be eligible to submit a late-breaking abstract from Aug. 23 – Sept. 12 at 5 p.m. PDT.

Thank You to Our Organizers

34th Annual Meeting Organizers

Ana Carrizosa Anderson, PhD – *Harvard Medical School*
Marianne Davies, DNP, AOCNP – *Yale School of Nursing*
Stefani Spranger, PhD – *Koch Institute for Integrative Cancer Research at MIT*
Ahmad A. Tarhini, MD, PhD – *Emory University and Winship Comprehensive Cancer Center*

World Immunotherapy Council's 3rd Young Investigator Symposium Organizers

Samir N. Khleif, MD – *Georgetown University*
Jose A. Lopez-Martin, MD, PhD – *12 de Octubre University Hospital & Research Institute*
Brad Nelson, PhD – *BC Cancer – Deeley Research Centre*
Graham P. Pawelec, PhD – *University of Tuebingen*
Barbara Seliger, MD, PhD – *Martin Luther University Halle-Wittenberg*
Joe Yeong, MBBS, PhD – *Singapore General Hospital*

Novel Multi-Targeted Therapeutic Platforms Organizers

Alessandra Cesano, MD, PhD – *NanoString Technologies, Inc.*
Edward Cha, MD, PhD – *Genentech*
Leena Gandhi, MD, PhD – *Eli Lilly*
Salil Patel, PhD – *Bristol-Myers Squibb*
Eric Rubin, MD – *Merck & Co., Inc.*

Workshop on Intratumoral Immunomodulation Organizers

Nina Bhardwaj, MD, PhD – *The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai*
Adi Diab, MD – *The University of Texas MD Anderson Cancer Center*

Primer on Tumor Immunology and Cancer Immunotherapy™ Organizers

Michael Curran, PhD – *The University of Texas MD Anderson Cancer Center*
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

Grant Writing Workshop Organizers

David H. Aggen, MD, PhD – *Columbia University Medical Center/NYPH*
Ana Carrizosa Anderson, PhD – *Harvard Medical School*
Lorenzo Falchi, MD – *Columbia University Medical Center*
Saman Maleki, PhD – *Western University*
Claire I. Vanpouille-Box, PhD – *Weill Cornell Medical College*



34th Annual Meeting & Pre-Conference Programs

SITC 2019

Gaylord National Hotel & Convention Center **Nov. 6-10**

NATIONAL HARBOR, MARYLAND

The SITC Annual Meeting and Primer on Tumor Immunology and Cancer Immunotherapy™ are approved for *AMA PRA Category 1 Credit™*, ANCC contact hours, and ACPE continuing education units. Attendees may also earn MOC points. For CE and MOC information and eligibility, visit sitcancer.org/2019.



Society for Immunotherapy of Cancer

SITC 2019: The Premier Gathering Place for the Cancer Immunotherapy Field

With each passing year, the cancer immunotherapy field evolves to produce more ground-breaking research and effective treatment options for patients fighting a host of devastating diseases. Thanks to the advances the field has produced, these patients, and the patients of tomorrow, have a brighter future.

But these advances don't occur in a vacuum or happen accidentally. They require collaboration, funding, learning, discussion and a place where the sharpest minds and most dedicated individuals of the cancer immunotherapy field can gather. That is exactly what the Society for Immunotherapy of Cancer's 34th Annual Meeting & Pre-Conference Programs (SITC 2019) provide.

As the world's largest conference solely focused on cancer immunotherapy, SITC 2019 hosts researchers, clinicians, regulators and members of industry from every corner of the globe as they come together to work towards the common goal of improving cancer patient outcomes.

What's New at SITC 2019

Every year, our goal is to make our Annual Meeting as impactful as possible. SITC 2019 is no different. Here are new elements that will help us achieve that goal:

- More oral presentation spots than ever before
- More travel awards are available than any previous SITC Annual Meeting
- The new Career Connections program will connect candidates with interested employers
- Additional Poster Symposium held Thursday night
- Hematologic Malignancies session organized in collaboration with the American Society of Hematology (ASH)

Meeting Details

SITC 2019 • Nov. 6–10, 2019

Gaylord National Hotel & Convention Center, National Harbor, Md.

Early SITC 2019 registration deadline: Oct. 9, 2019

Housing reservation deadline: Oct. 14, 2019

For more information on registration and housing for SITC 2019, please visit sitcancer.org/2019

Pre-Conference Programs

Wednesday, Nov. 6, 2019

World Immunotherapy Council's 3rd Young Investigator Symposium: 8 a.m. – 1 p.m.

SITC and the World Immunotherapy Council (WIC) are dedicated to advancing cancer immunotherapy and the future leaders of the field. This program will provide the opportunity for young scientists and future worldwide leaders to interact, fulfilling WIC's mission to facilitate rapid development and global dissemination of cancer immunotherapies through scientific exchange.

Novel Multi-Targeted Therapeutic Platforms: 2 – 6:30 p.m.

This program will address the critical scientific, manufacturing and clinical questions that arose as T-cell engagers, other multi-targeted antibodies and related platforms, such as cytokine fusions and cancer vaccines, increasingly make their way into the clinic.

Thursday, Nov. 7, 2019

Primer on Tumor Immunology and Cancer Immunotherapy™: 8 a.m. – 5 p.m.

The understanding of cancer immunobiology has increased dramatically in recent years, leading to the development of novel immune-based treatments to improve cancer patient outcomes. This program is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

Workshop on Intratumoral Immunomodulation: 8 a.m. – 5 p.m.

In this workshop, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with their implications for current and forthcoming immunotherapy treatments.

Grant Writing Workshop: The study section black box: A look inside the grant review process: 6 – 8 p.m.

This program offers insight into the grant submission process, outlines how to navigate funding opportunities, addresses government and private sector grant submissions, details how to revise a grant for resubmission and offers a "mini-study section," allowing attendees to experience a study section's grant proposal evaluation.

For more information on SITC's Pre-Conference Programs, please visit sitcancer.org/2019

Annual Meeting

Thursday, Nov. 7 –
Sunday, Nov. 10, 2019

The Annual Meeting features cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting highlights updates on major national and international initiatives coming from academia, government and industry, as well as important society projects.

The SITC Annual Meeting brings together over 5,000 attendees representing more than 35 countries, disease states and specialties coming together to advance the field of cancer immunotherapy.

Sessions of Special Interest to a Clinical Audience

- Autoimmunity, Toxicity and Cancer Immunotherapy
- Clinical Management
- Combination Phase 1-2 Clinical Trials
- Hematologic Malignancies
- High-Impact Clinical Trials
- Immune Checkpoints: Newer Targets and Updates on Combinations
- Immunotherapy Advances in Skin Cancer
- Innovations in Cellular Therapy for Therapeutically Targeting Advanced Malignancies
- Single Agent Phase 1 Clinical Trials
- Virus Driven Cancers

For more information on SITC's Annual Meeting, please visit sitcancer.org/2019



Thank You to Our Annual Program Committee

Annual Program Committee Chair • Sandra Demaria, MD – Weill Cornell Medicine

34th Annual Meeting Committee Members

- Davide Bedognetti, MD, PhD – *Sidra Medical and Research Center*
- Patrick Hwu, MD – *The University of Texas MD Anderson Cancer Center*
- Krista M. Rubin, MS, FNP-BC – *Massachusetts General Hospital*
- Dario A.A. Vignali, PhD – *University of Pittsburgh*

SITC 2019
Gaylord National Hotel & Convention Center
Nov. 6-10
NATIONAL HARBOR, MARYLAND